• 1
    Hammer SM, Eron JJ Jr et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300: 555570.
  • 2
    Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998; 338: 853860.
  • 3
    Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 21612167.
  • 4
    Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235242.
  • 5
    Bongiovanni M, Bini T, Adorni F et al. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther 2003; 8: 209214.
  • 6
    Marcelin AG, Affolabi D, Lamotte C et al. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. J Med Virol 2004; 74: 1620.
  • 7
    Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007; 60: 11951205.
  • 8
    Arribas JR, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40: 280287.
  • 9
    Nunes EP, Oliveira MS, Almeida MM et al. 48–week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART—the KalMo Study. 16th International Conference on AIDS. Toronto, ON, August 2006 [Abstract TUAB0102].
  • 10
    Pulido F, Arribas JR, Delgado R et al. for the OK04 Study Group. Lopinavir-ritonavir monotherapy vs. lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22: F1F9.
  • 11
    Cameron DW, Da Silva BA, Arribas JR et al. A 96–week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy vs. efavirenz combination therapy. J Infect Dis 2008; 198: 234240.
  • 12
    Gathe JC, Mayberry C, Miguel B, Nemecek J, Yeh R. Long-term follow-up of IMANI–1: pilot study of the safety and efficacy of lopinavir/ritonavir (LPV/r) as single agent therapy (SAT) in HIV-1 antiretroviral (ARV)-naïve patients. 8th Annual International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2006 [Abstract P5].
  • 13
    Gathe JC, Yeh RF, Mayberry C et al. Single-agent therapy with lopinavir/ritonavir suppresses plasma HIV-1 viral replication in HIV-1 naïve subjects: IMANI-2 48-week results. 4th IAS Conference. Sydney, Australia, July 2007 [Abstract WePeB034].
  • 14
    Delfraissy JF, Flandre P, Delaugerre C et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naïve HIV-infected patients. AIDS 2008; 22: 385393.
  • 15
    Delaugerre C, Flandre P, Chaix ML et al. Protease inhibitors resistance analysis in the MONARK trial comparing first-line lopinavir/ritonavir monotherapy to lopinavir/ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53: 29342939.
  • 16
    Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev 2008; 10: 414.
  • 17
    Conradie F, Sanne I, Venter W, Eron J. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naïve patient. AIDS 2004; 18: 10841085.
  • 18
    Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18: 19651966.
  • 19
    Gutmann C, Opravil M, Fux C et al. Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and associated with low nadir CD4 count in the MOST Study. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, QC, February 2009 [Abstract 578].
  • 20
    Letendre SL, Van Den Brande G, Hermes A et al. for the HIV Neurobehavioral Research Center Group. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 2007; 45: 15111517.
  • 21
    Capparelli EV, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19: 949952.
  • 22
    Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Cerebrospinal fluid and plasma HIV-1 RNA level and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis 2004; 36: 823828.
  • 23
    Ghosn J, Chaix ML, Peytavin G et al. Absence of HIV-1 shedding in male genital tract after one year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J Antimicrob Chemother 2008; 61: 13441347.
  • 24
    Schackman BR, Scott CA, Sax PE et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45: 10621070.